IL6 and bronchopulmonary dysplasia: These treatments lowered the levels of inflammatory mediators like IL−6 and TNF-α [197], and the expression of angiotensin II, angiotensin II type 1 receptor, and angiotensin-converting enzyme [198], which are involved in the development of BPD.